F2RL1 and atopic eczema: Taken together, these attributes highlight PCG as a promising candidate to overcome the pharmacokinetic and safety barriers that have hindered the clinical translation of previous PAR2-targeted agents, offering a promising therapeutic approach for conditions such as atopic dermatitis.